Sun Pharma's Unloxcyt Earns NCCN Category 2A Status for Advanced Skin Cancer
NCCN grants Sun Pharma's Unloxcyt Category 2A status for advanced skin cancer, strengthening payer coverage and prescribing confidence for the systemic therapy.
Topic
Unloxcyt
Topic